Zobrazeno 1 - 9
of 9
pro vyhledávání: '"M A Satybaldyeva"'
Autor:
N V Seredavkina, T M Reshetnyak, M A Satybaldyeva, L N Kashnikova, T A Temnikova, E L Nasonov
Publikováno v:
Терапевтический архив, Vol 91, Iss 5, Pp 19-25 (2019)
The aim of the study was to evaluate the anti - Xa - activity (aXa) of selective and non - selective factor Xa inhibitors in patients with systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) patients according to clinical implicati
Externí odkaz:
https://doaj.org/article/fadf667304684486bfefcc3438e28684
Autor:
G A Movsisyan, T V Martynyuk, K V Mershin, N M Danilov, M A Satybaldyeva, T M Reshetnyak, R S Akchurin, E L Nasonov, I Ye Chazova
Publikováno v:
Терапевтический архив, Vol 89, Iss 9, Pp 93-99 (2017)
Chronic thromboembolic pulmonary hypertension (CTEPH) is one of the potentially curable forms of pulmonary hypertension, in which pulmonary thromboendarterectomy is the gold standard treatment. However, over the last decade, great attention has been
Externí odkaz:
https://doaj.org/article/dbabec83363647a797540631a48c5d57
Publikováno v:
Научно-практическая ревматология, Vol 56, Iss 6, Pp 692-696 (2019)
Objective: to determine risk factors (RFs) for venous thromboembolic events (VTE) in patients with rheumatoid arthritis (RA).Subjects and methods: The investigation enrolled 374 patients (311 women and 63 men) with a reliable diagnosis of RA who met
Externí odkaz:
https://doaj.org/article/713e067b6d7c45c18352145041b39b05
Autor:
M. A. Satybaldyeva, N. V. Seredavkina, S. I. Glukhova, I. N. Gorskikh, T. M. Reshetnyak, E. L. Nasonov
Publikováno v:
Научно-практическая ревматология, Vol 55, Iss 5, Pp 514-520 (2017)
Objective: to assess the psychometric properties (reliability, sensitivity, and validity) of a Russian-language version of the VEINES-QOL/Sym questionnaire in patients with rheumatic diseases and lower extremity chronic venous diseases.Subjects and m
Externí odkaz:
https://doaj.org/article/867f2a398f39461b805439e00a246157
Autor:
M. A. Satybaldyeva, T. M. Reshetnyak, N. V. Seredavkina, S. I. Glukhova, D. E. Karateev, E. L. Nasonov
Publikováno v:
Научно-практическая ревматология, Vol 54, Iss 4, Pp 398-403 (2016)
Objective: to determine the incidence and risk factors of venous thromboembolic events (VTEE) in patients with rheumatoid arthritis (RA).Subjects and methods. The investigation enrolled 362 patients (302 women and 60 men) with RA fulfilling the 2010
Externí odkaz:
https://doaj.org/article/47da47f630764a3abc12c44877c66f67
Autor:
M. A. Satybaldyeva
Publikováno v:
Научно-практическая ревматология, Vol 54, Iss 4, Pp 456-462 (2016)
The literature review gives the data of recent investigations that have demonstrated that rheumatoid arthritis increases the incidence of venous thromboembolic events. It considers the pathogenesis of thrombosis in chronic inflammatory diseases and t
Externí odkaz:
https://doaj.org/article/90106ad356484f9594e6e99e7a776bf6
Autor:
M. A. Satybaldyeva, T. M. Reshetnyak
Publikováno v:
Научно-практическая ревматология, Vol 54, Iss 2, Pp 219-226 (2016)
The vitamin K antagonist warfarin is an essential medicine from a group of anticoagulants, which is used to treat antiphospholipid syndrome (APS). However, it has a number of disadvantages especially in patients who need longterm and frequently lifet
Externí odkaz:
https://doaj.org/article/62bb5273712b4667a2fdb6b47cac5a6b
Autor:
N. V. Seredavkina, L N Kashnikova, T. M. Reshetnyak, M. A. Satybaldyeva, Nasonov El, T A Temnikova
Publikováno v:
Терапевтический архив, Vol 91, Iss 5, Pp 19-25 (2019)
The aim of the study was to evaluate the anti - Xa - activity (aXa) of selective and non - selective factor Xa inhibitors in patients with systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) patients according to clinical implicati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6595494e91b261e22d14fff6ae35524d
https://pubmed.ncbi.nlm.nih.gov/32598672
https://pubmed.ncbi.nlm.nih.gov/32598672
Autor:
K. V. Mershin, E. L. Nasonov, I Ye Chazova, Akchurin Rs, Tamila Martynyuk, M. A. Satybaldyeva, Nikolai M. Danilov, G. A. Movsisyan, T. M. Reshetnyak
Publikováno v:
Терапевтический архив, Vol 89, Iss 9, Pp 93-99 (2017)
Chronic thromboembolic pulmonary hypertension (CTEPH) is one of the potentially curable forms of pulmonary hypertension, in which pulmonary thromboendarterectomy is the gold standard treatment. However, over the last decade, great attention has been
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39f5e5539ec5010d85cffda7e495237a
https://pubmed.ncbi.nlm.nih.gov/29039836
https://pubmed.ncbi.nlm.nih.gov/29039836